CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discoveryLiuxin Lu, Renren Bai, Junjie Li et al.|Medicinal Research Reviews|2024Cited by 43
Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: <i>De Novo</i> Molecular Generation Based on a Low Activity Lead CompoundHong Cai, Renren Bai, Xinhua Ni et al.|Journal of Medicinal Chemistry|2024Cited by 18
Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4Xiaoying Jiang, Renren Bai, Liuxin Lu et al.|Journal of Medicinal Chemistry|2024Cited by 15
Small-molecule agents for treating skin diseasesHong Cai, Renren Bai, Hao Wen et al.|European Journal of Medicinal Chemistry|2024Cited by 3
Discovery of dibenzyl amide derivatives as novel CXCR4 modulators against inflammatory bowel diseaseXiaoying Jiang, Renren Bai, Liuxin Lu et al.|European Journal of Medicinal Chemistry Reports|2024Cited by 1